

Validating a self-administered, language-independent iPad-based test for assessment and monitoring of cognitive impairment in patients with multiple sclerosis (MS)

Submission date 12/02/2018	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/02/2018	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 22/06/2020	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Multiple sclerosis (MS) is a condition that affects the brain and spinal cord. Cognitive impairment is common in patients with MS however it is not routinely assessed in the clinic setting. Cognitive impairment causes a decline in memory and thinking skills. The currently available reference tests for assessing cognitive impairment in MS are typically long and need an expert to administer the test. Researches have developed a 5-minute iPad based test that is self-administered and language independent to measure cognitive dysfunction in patients with MS. This test is called an Integrated Cognitive Assessment tool (or ICA). The aim of this study is to validate an iPad-based test in assessing cognitive dysfunction in patients with MS to show that the test outcome has construct validity with BICAMS (Brief International Cognitive Assessment for MS).

Who can participate?

MS patients and healthy controls that are within the same age-range.

What does the study involve?

All participants are randomly allocated to the order in which they undergo two difference types of cognitive assessment. Participants take the recently developed integrated cognitive assessment (ICA) test on an iPad that takes about five minutes. Each participant also takes the BICAMS test that lasts about 20 minutes. BICAMS is a battery of three pen and paper test. This includes the Symbol Digit Modalities Test (SDMT) which measures cognitive processing speed, the California Verbal Learning Test and the Brief Visuospatial Memory Test. In the follow-up session, each participant takes the SDMT test, and the ICA iPad test.

What are the possible benefits and risks of participating?

Participants will benefit from a comprehensive cognitive assessment, and a follow-up after

about four month. There are no risks associated with participating in the study, particularly because the study only contains behavioral cognitive assessments (i.e. pen and paper tests, and a computerized test).

Where is the study run from?

MS specialist clinic, Aria Medical Complex (Iran)

When is the study starting and how long is it expected to run for?

December 2017 to July 2018

Who is funding the study?

Cognativity Ltd (UK)

Who is the main contact?

Dr Seyed-Mahdi Khaligh-Razavi (Scientific)

Contact information

Type(s)

Scientific

Contact name

Dr Seyed-Mahdi Khaligh-Razavi

Contact details

Royan Institute

Banihashem Square

Tehran

Iran

19395-4644

Additional identifiers

Protocol serial number

CGN-1702

Study information

Scientific Title

A brief language-independent and self-administered computerized tool for cognitive assessment in multiple sclerosis (MS)

Study objectives

The aim of this study is to validate an iPad-based test in assessing cognitive dysfunction in patients with MS. We will show that the test outcome has construct validity with BICAMS (Brief International Cognitive Assessment for MS).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Research Ethics Committee of Royan Institute, 08/08/2017, ref: IR.ACECR.ROYAN.REC.IR.ACECR.ROYAN.REC.1396.98

Study design

Single-center observational case-control study

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Multiple sclerosis

Interventions

After enrollment in the study, both MS and healthy participants go through two types of cognitive assessment in a randomized order. Participants take the recently developed integrated cognitive assessment (ICA) test on an iPad that takes about five minutes. Each participant also take the BICAMS test that lasts about 20 minutes. BICAMS is a battery of three pen and paper tests:

1. Symbol Digit Modalities Test (SDMT) which is a measure of cognitive processing speed and takes about 5 minute
2. The initial learning trials of the California Verbal Learning Test 2nd Edition (CVLT-II), which takes 10 minutes to complete
3. The Brief Visuospatial Memory Test-Revised (BVRT-R), which takes 5 minutes

In the follow-up session, each participant takes the SDMT test (~5 min duration), and the ICA iPad test (~5min) in a randomized order.

Intervention Type

Behavioural

Primary outcome(s)

1. Cognitive dysfunction is measured using the BICAMS score at baseline, and four months
2. Cognitive dysfunction is measured using the Integrated Cognitive Assessment (ICA) score at baseline and four months

Key secondary outcome(s)

1. Reliability for SDMT is measured by correlating SDMT categorizations (i.e. cognitively intact, mildly impaired, severely impaired) made on the first visit and the second visit
2. Reliability for ICA is measured by correlating ICA categorizations (i.e. cognitively intact, mildly impaired, severely impaired) made on the first visit and the second visit

Completion date

30/07/2018

Eligibility

Key inclusion criteria

1. Definite diagnosis of MS in all the following categories, regardless of age, sex and education level:
 - 1.1. RR: relapsing remitting
 - 1.2. PP: primary progressive
 - 1.3. SP: secondary progressive
2. Healthy controls within an age-range similar to the MS patients

Participant type(s)

Mixed

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

174

Key exclusion criteria

1. Moderate to Severe Depression as measured by Beck's Score
2. Interfering motor problems (e.g. upper limb motor dysfunction)
3. Vision problems that cannot be corrected with eye-glasses such that it prevents participant from reading
4. Presence of other neurological disorders medical illnesses that affect brain function and cognition
5. History of seizures
6. History of drug or alcohol abuse

Date of first enrolment

05/01/2018

Date of final enrolment

30/04/2018

Locations**Countries of recruitment**

Iran

Study participating centre

MS Specialist Clinic Aria Medical Complex
No. 218, Mollasadra St

Tehran
Iran
143591537

Sponsor information

Organisation
Cognetivity Ltd

Organisation
Royan Institute

Funder(s)

Funder type
Industry

Funder Name
Cognetivity Ltd

Results and Publications

Individual participant data (IPD) sharing plan

The current data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2020	22/06/2020	Yes	No